OncClubAll Oncology NewsPipeline Report
InsightsMedical World NewsOncChatsOncLive News Network®OncLive TVPeer ExchangePodcastsRapid ReadoutsThe Talk
Conference CoverageConference Listing
Giants of Cancer CarePER EventsScientific InterchangesState of the Science Summit / IPCWebinars
Partners
Oncology Live®Oncology FellowsSupplements And Featured PublicationsAll Publications
CME/CE
Biomarker ConsortiumInteractive ToolsLearning ModulesPresentationsSponsored
Print SubscriptioneNewsletter
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
Business Management
CAR T-cell Therapy
COVID-19
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-OncologyImmuno-OncologyImmuno-OncologyImmuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Nursing News
Pediatric Oncology
Precision Medicine in Oncology®Precision Medicine in Oncology®
Sarcomas/TGCT
Supportive Care
Spotlight -
  • REGISTER TODAY to explore data on a novel second-generation BTK inhibitor for adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
  • Share your views with OncChats
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
Business Management
CAR T-cell Therapy
COVID-19
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-OncologyImmuno-OncologyImmuno-OncologyImmuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Nursing News
Pediatric Oncology
Precision Medicine in Oncology®Precision Medicine in Oncology®
Sarcomas/TGCT
Supportive Care
    • Partners
    • CME/CE
Advertisement

Optimizing Systemic Therapy for Chronic Lymphocytic Leukemia

home / peer-exchange / cll-systemic-therapy
Advertisement
First-Line Therapy for Older Patients With CLL

EP. 1: First-Line Therapy for Older Patients With CLL

January 4th 2019
Ibrutinib Versus FCR for Younger Patients With CLL

EP. 2: Ibrutinib Versus FCR for Younger Patients With CLL

January 4th 2019
Novel Combination Therapies for CLL

EP. 3: Novel Combination Therapies for CLL

January 4th 2019
Prognostic Factors in CLL

EP. 4: Prognostic Factors in CLL

January 4th 2019
Emerging BTK Inhibitors for CLL

EP. 5: Emerging BTK Inhibitors for CLL

January 4th 2019
Real-World Data for CLL

EP. 6: Real-World Data for CLL

January 4th 2019
Advertisement
Venetoclax + Rituximab in Relapsed CLL

EP. 7: Venetoclax + Rituximab in Relapsed CLL

January 4th 2019
Toxicity Management With Venetoclax for CLL

EP. 8: Toxicity Management With Venetoclax for CLL

January 4th 2019
CD20-Targeted Antibodies With Novel Agents for CLL

EP. 9: CD20-Targeted Antibodies With Novel Agents for CLL

January 4th 2019
Resistance to Venetoclax in CLL

EP. 10: Resistance to Venetoclax in CLL

January 4th 2019
Resistance to Ibrutinib in CLL

EP. 11: Resistance to Ibrutinib in CLL

January 4th 2019
Duvelisib for Relapsed/Refractory CLL

EP. 12: Duvelisib for Relapsed/Refractory CLL

January 4th 2019
Advertisement
CAR T-Cell Therapy for CLL

EP. 13: CAR T-Cell Therapy for CLL

January 4th 2019
Take-Home Messages From ASH 2018 in CLL

EP. 14: Take-Home Messages From ASH 2018 in CLL

January 4th 2019
Standardizing MRD Testing for CLL

EP. 15: Standardizing MRD Testing for CLL

January 4th 2019

Latest Conference Coverage

Lung Responses to Atezolizumab/Bevacizumab Linked With OS in HCC and Pulmonary Metastasis

Second-Line Regorafenib Demonstrates Safety in Advanced HCC, Irrespective of Prior Treatment

First-line Toripalimab Plus Sorafenib Elicits Responses in Unresectable Hepatocellular Carcinoma

Data for Luspatercept Highlight Evolving Treatment Landscape in Lower-Risk MDS

View More Latest Conference Coverage
Advertise
About OncLive
Editorial Board
CancerNetwork.com
CGTlive.com
CureToday.com
OncNursingNews.com
TargetedOnc.com
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.
Home
About Us
News
Contact